Absci (ABSI) Shares Outstanding (2020 - 2026)
Absci (ABSI) posted Shares Outstanding (Entity) of $155.9 million for Q1 2026, up 2.9% sequentially from $151.5 million in Q4 2025, and up 22.22% YoY from $127.6 million in Q1 2025.
Absci (ABSI) Shares Outstanding (2020 - 2026) Analysis & Trends
Absci has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $155.9 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 22.22% year-over-year to $155.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $155.9 million (up 22.22% YoY) and the FY2025 annual result came in at $151.5 million, up 31.34% from the prior year.
- Shares Outstanding (Entity) climbed to $155.9 million in Q1 2026 per ABSI's latest filing, from $151.5 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $155.9 million in Q1 2026 and troughed at $92.4 million in Q4 2022.
- A 5-year average of $113.7 million and a median of $113.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) surged 425.94% in 2022, then retreated 0.38% in 2023.
- Over 5 years, Shares Outstanding (Entity) stood at $92.4 million in 2022, then rose by 0.73% to $93.1 million in 2023, then gained by 23.93% to $115.4 million in 2024, then surged by 31.34% to $151.5 million in 2025, then advanced by 2.9% to $155.9 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $155.9 million, $151.5 million, and $150.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | 157.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 157.47 Mn |
| Mar 31, 2026 | 152.96 Mn |
| Dec 31, 2025 | 136.78 Mn |
| Sep 30, 2025 | 143.77 Mn |
| Jun 30, 2025 | 127.59 Mn |
| Mar 31, 2025 | 124.46 Mn |
| Dec 31, 2024 | 110.24 Mn |
| Sep 30, 2024 | 113.61 Mn |
| Jun 30, 2024 | 112.93 Mn |
| Mar 31, 2024 | 99.39 Mn |
| Dec 31, 2023 | 92.03 Mn |
| Sep 30, 2023 | 92.22 Mn |
| Jun 30, 2023 | 91.83 Mn |
| Mar 31, 2023 | 91.48 Mn |
| Dec 31, 2022 | 90.85 Mn |
| Sep 30, 2022 | 91.11 Mn |
| Jun 30, 2022 | 90.67 Mn |
| Mar 31, 2022 | 90.27 Mn |
| Dec 31, 2021 | 49.69 Mn |
| Sep 30, 2021 | 73.29 Mn |